Russia’s cancer vaccine has arrived in the public imagination the way most geopolitical breakthroughs do: loudly, unevenly, and considerably ahead of the underlying science. Since late 2024, a cascade of claims has moved through social media and news aggregators insisting that Russia has already approved a cancer vaccine, that China is weeks away from endorsing it, and that the combined force of this Sino-Russian pharmaceutical partnership will destroy the Western oncology industry, a market variously described as worth $2.6 trillion, $3 trillion, and, depending on how motivated the poster seems, even more.
The number, it turns out, is approximately twelve times the actual size of the global cancer drug market. But the exaggeration is not the most important thing to understand about what is happening. The more important question is what is actually true, how far along the science really is, what the China-Russia medical cooperation genuinely involves, and under what circumstances, if any, a patient sitting in a hospital in Brussels, Birmingham, or Baltimore might one day access it.
The answer, in its shortest form, is: not yet, not soon, and not without navigating a set of structural walls that exist independently of political goodwill. But the longer answer is worth the journey. Because something is in motion here, even if it is moving more slowly and more cautiously than the headlines suggest. And the economic logic of what it could ultimately disrupt, once the clinical evidence actually exists, is real enough to take seriously.
…
Read the full article on Nspirement
Comments